Treatment of premenstrual syndrome with alprazolam: Results of a DoGble-blind, placebo controlled, randomized crossover clinical trial

Samuel Smith, John S. Rinehart, Vilma E. Ruddock, Isaac Schiff

Research output: Contribution to journalArticlepeer-review

Abstract

A double-blind, placebo-controlled, randomized multiple crossover study was designed to determine the effectiveness of alprazolam i n the treatment of premenstrual syndrome. Patients maintained daily diaries of 22 premenstrual symptoms for one pretreatment control cycle and four treatment cycles. Alprazolam 0.25 mg or placebo was administered three times daily from cycle day 20 until the second day of menstruation, at which time the dosage was tapered by one tablet per day to minimize withdrawal effects. The results of the clinical trial indicate that alprazolam is significantly more effective than placebo in relieving the severity of premenstrual nervous tension, mood swings, irritability, anxiety, depression, fatigue, forgetfulness, crying, cravings for sweets, abdominal bloating, abdominal cramps, and headache. The low incidence of side effects makes alprazolam an acceptable treatment for premenstrual syndrome for those women unresponsive to other therapies.

Original languageEnglish (US)
Pages (from-to)37-43
Number of pages7
JournalObstetrics and gynecology
Volume70
Issue number1
StatePublished - Jul 1987
Externally publishedYes

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'Treatment of premenstrual syndrome with alprazolam: Results of a DoGble-blind, placebo controlled, randomized crossover clinical trial'. Together they form a unique fingerprint.

Cite this